• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Systemic lupus erythematosus: An update on current pharmacotherapy and future directions
【24h】

Systemic lupus erythematosus: An update on current pharmacotherapy and future directions

机译：系统性红斑狼疮：当前药物治疗的最新进展和未来方向

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: In the last decade, the development of a number of potential drugs for lupus that target the pathogenesis of the disease at different levels has been witnessed. Despite a number of negative trials during this period, belimumab was recently approved for the treatment of adult seropositive lupus patients with mild-to-moderate disease activity. Areas covered: This review summarizes the results of the most recent drug trials in lupus and highlights the aspects that require further refinement and modification in order to facilitate positive results in new drug trials for lupus. Expert opinion: The success of a clinical trial depends on the efficacy of the study drug and its appropriate dosing. Several other factors play a major role in the success of trials, including the patient inclusion criteria, the choice of evidence-based study outcomes and endpoints and other aspects of study design that are described in this review.
机译：简介：在过去的十年中，目睹了针对狼疮的多种潜在药物的开发，这些药物针对疾病的发病机理具有不同的水平。尽管在此期间进行了许多阴性试验，但是贝利木单抗最近被批准用于治疗具有轻度至中度疾病活动的成人血清反应阳性的狼疮患者。涵盖的领域：本综述总结了狼疮的最新药物试验结果，并着重指出了需要进一步改进和修改的方面，以利于狼疮新药试验的积极结果。专家意见：临床试验的成功取决于研究药物的功效及其适当的剂量。其他一些因素在试验的成功中起着重要作用，包括患者纳入标准，基于证据的研究结果和终点的选择以及本评价中描述的研究设计的其他方面。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号